GMED Stock — Globus Medical, Inc.

Globus Medical, Inc. (GMED)

Updated October 16, 2026.

GMED is a Stock. Total return is 468.2% over the past 14.2 years, 131.9 points behind SPY at 600.1%.

Globus Medical develops and commercializes medical devices and solutions for musculoskeletal disorders, including spine implants, orthopedic trauma products, joint reconstruction systems, and robotic surgical guidance platforms. The company does not currently have an established distribution program. This stock may appeal primarily to growth-oriented investors seeking exposure to the medical device sector.

GMED performance versus SPY

Price and return data through 2026-10-16.

Total return is 468.2% over the past 14.2 years, 131.9 points behind SPY at 600.1%. Over the past year its total return — price change plus distributions reinvested — is 31.0%. Its deepest 1-year drawdown was 24.3%.

GMED key facts

Asset type

Stock

Asset class

Equity

Inception date

08/03/2012

Distribution frequency

None

Last close

$76.71 (as of 2026-10-16)

Market cap

$8,578,618,682

Average volume

1940372.0

Beta

0.959

Payout ratio

0.0%

P/E ratio

19.67

Forward P/E

13.8696

EPS

$3.90

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

GMED risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 24.3%.

Who may consider GMED — and who may not

It is a weaker fit for investors who need monthly cash flow (GMED does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on GMED

• All tickers starting with G

Tagged: Healthcare.

Frequently asked questions